Ipsen understands that working in partnership with those around us is a cornerstone of achieving meaningful change for patients. As a growing organisation with a dynamic and agile mindset, we are continuously trying to identify ways in which Ipsen can support the U.K. & Ireland healthcare ecosystem. It is our aim to meet both the needs of patients and the community who care for them.
Whether working with world-leading scientists investigating cutting-edge science, partnering with the NHS and HSE to improve care for patients, or working with patient groups on disease awareness initiatives, we strive to establish partnerships with strong ethical foundations and bold ambitions.
Our contribution
Ipsen invests significantly in Ireland as part of our ongoing commitment to drive positive change for patients, supporting the HSE, and offering exceptional people a great place to work. We have successfully brought eight new treatments or indications to the U.K. & Ireland market in recent years. Our bold ambition is to launch at least one new product or meaningful indication each year.
Every year, we invest millions into the British economy, generating meaningful impact to society. From 2019 to October 2021 Ipsen invested around £86.8m into our U.K. & Ireland sites, developing facilities as well as our clinical and R&D programmes.
Our collaborations
As a company we pride ourselves on our ability to work in partnership with our customers identifying opportunities where our products can make a difference to patients’ lives within the therapy areas of oncology, neuroscience, and rare diseases.
We take a patient centric approach in all that we do, working collaboratively with our customers to develop innovative patient support programs. One of these programs allows patients/carers the ability to self-administer their medication at home allowing more independence. This was especially important during the Covid pandemic where there was a severe burden on the health service.
We are continuously looking at innovative ways to support patients manage their disease and are currently piloting an app to help patients within the neuroscience disease area record and manage symptoms of their disease.
The U.K. & Ireland are world-leading hubs for Life Science innovation. Ipsen believes that an effective working relationship with the U.K. & Irish governments is a crucial part of this success.
We understand that building pioneering partnerships with key stakeholder groups is essential to unlock positive change for patients with rare and underserved conditions, collaborating with the government is key to improving patients’ lives through specialty care in Ireland across the country, with the pandemic being a catalyst for collaboration and enhanced trust between the pharmaceutical sector in Ireland (& internationally) and policy makers. Not only are biopharmaceutical companies working together with governments and regulatory bodies to ensure the delivery of safe vaccines, but biopharmaceutical companies have also been able to ensure the continuity of supply of vital medicines. Ipsen has been a long-term employer in the Dublin West area since it first established its Blanchardstown site in 1989. We endeavour to influence positive change among policy makers, locally in Dublin and Ireland, to ensure the needs of patients with rare and life-threatening diseases are met.
Through proactively engaging with the government, policymakers, and other elected representatives, we strive to improve patients’ health and transform lives.
Ipsen understands that working in partnership with those around us is a cornerstone of achieving meaningful change for patients. We strive for genuine collaboration with advocacy groups, always putting patients at the heart of everything we do. We support the work of many patient advocacy groups across the U.K. & Ireland, working in partnership, we aim to help people and families affected by debilitating conditions to live better lives.
Improving the lives of patients is what drives us at Ipsen. We view our work with patient advocacy groups as a pivotal part of delivering on that ambition. At Ipsen we pride ourselves on working with patient advocacy groups in a way that reflects our core ethical values and maintains integrity. We strive to build long-term partnerships that offer mutual value, support the independent initiatives of patient advocacy groups and help them achieve their ambitions for patients.
Over the past couple of years, Ipsen, like many other biopharmaceutical companies, has transitioned away from supporting patient organisations primarily through the mechanism of grants & donations. As such, we no longer have a designated grants & donations allocation each year. Of course, working with and supporting patient groups is still critically important for us – our mission to support better outcomes for patients is uppermost for the company. We are keen to explore projects where we can collaborate, be this through developing partnership activities or through areas like sponsorship.
If you are representing a patient organisation or charity and would like to speak to us about a potential partnership, please contact us via the Contact Us button on this website.
CRSC-GB-000220
October 2025